trial with title COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 - Australia

Who is eligible to participate?

The COMMANDS Trial may be an option for those who meet the following criteria:
• Are 18 years of age and older
• Have been diagnosed with MDS with anaemia
• Require blood cell transfusions 

If you meet these initial criteria, we invite you to take the prescreening questionnaire to see if you may qualify to participate in this study.

Data privacy: We value your privacy. The information that you provide here will only be used by the study sponsor, its affiliates and agents to fulfill your request to learn more about, and assess your eligibility for, the COMMANDS study.

Check if you are eligible Enter contact details Select a site

Have you been diagnosed with myelodysplasia/myelodysplastic syndromes (MDS)?

More about study participation.

Participation in the study lasts approximately six years (and may be shorter or longer for certain participants). This includes: 

  • a screening period of approximately 35 days,
  • an initial 24-week treatment period (which may be extended if certain criteria are met and if you continue to benefit from the treatment), and
  • a follow-up period where you will be contacted approximately every 12 weeks to ask how you are doing (follow up on progress). 

The study drug being used in the COMMANDS Trial is is a protein that aims to help increase the production of red blood cells in bone marrow. The study drug will be administered as an injection every three weeks during the treatment period.